This article, written with co-authors Bruce H. Kobayashi, Joshua D. Wright, and Douglas H. Ginsburg, examines the economics of litigation and settlement of patent disputes arising from Paragraph IV Abbreviated New Drug Application (ANDA) filings under the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) within the framework set out in Actavis.
Why a hotel room in New York costs $500 a night
In a recent op-ed in The Wall Street Journal titled “Why a Hotel Room in NY Costs $500,” Michael Salinger (CRA consultant and Boston University professor) and...